肝脏是结直肠癌转移最常见的部位。多模式治疗包括肝切除术，对于有选择的结直肠癌肝转移患者具有潜在的治愈作用并延长生存期。然而，CRLM的治疗仍然具有挑战性，因为复发是常见的，在治愈意图治疗下患者的预后差异很大，临床病理学特征和基于组织的分子生物标志物基本上无法精确预测。由于细胞中大多数功能信息存在于蛋白质组中，循环蛋白质组生物标志物可能有助于理解CRLM的分子复杂性并确定潜在的预后分子亚型。高通量蛋白质组学加速了一系列应用，包括用于生物标记物发现的液体活检蛋白质组分析。此外，这些蛋白质组生物标志物甚至可以在CRLM切除前提供非侵入性的预后信息。本综述评估了最近发现的CRLM循环蛋白质组生物标志物。我们还强调了将这些发现转化为临床应用所面临的一些挑战和机遇。 ©2023年作者。

The liver is the most common site of metastasis in colorectal cancer. Multimodal treatment, including liver resection, is potentially curative and prolongs survival for selected patients with colorectal liver metastases (CRLM). However, the treatment of CRLM remains challenging because recurrence is common, and prognosis varies widely between patients despite curative-intent treatment. Clinicopathological features and tissue-based molecular biomarkers, either alone or in combination, are insufficient for accurate prognostication. As most of the functional information in cells resides in the proteome, circulating proteomic biomarkers may be useful for rationalising the molecular complexities of CRLM and identifying potentially prognostic molecular subtypes. High-throughput proteomics has accelerated a range of applications including protein profiling of liquid biopsies for biomarker discovery. Moreover, these proteomic biomarkers may provide non-invasive prognostic information even before CRLM resection. This review evaluates recently discovered circulating proteomic biomarkers in CRLM. We also highlight some of the challenges and opportunities with translating these discoveries into clinical applications.© 2023 The Authors.